Effect of Amphotericin B on Treatment of Chronic Rhinosinusitis: A Double-blind Randomized Clinical Trial


1 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

2 Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

3 Department of Otolaryngology, Resident of Otolaryngology, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

4 Department of Otolaryngology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

5 Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran


Abstract Background: Chronic rhinosinusitis (CRS) is the inflammation of paranasal sinusmucousmembranes. Considering the influence of fungi on chronic rhinosinusitis and different results concerning the effect of Amphotericin B on improvement of this condition; this study aimed to determine the effect of topical Amphotericin B on improvement of the symptoms in patients with CRS. Methods: In this double-blind randomized clinical trial, 80 patients with chronic rhinosinusitis who visited the allergy clinic of BaqiyatallahHospital fromJune toOctober 2014were randomly allocated to two groups; the first group received 10 cc topical lavage of Amphotericin B (5 cc each nostril for every 12 hours) and the second group received placebo for threemonths. Symptoms, nasal mucusa smear, serumlevel of inflammatory cytokines, CT scan and rhinoscopy score changes were evaluated in both groups after threemonths. Results: Fifty-five male and 25 female patients were evaluated in two groups. The mean age was 26.1  2.36 and 27.9  1.59 years in intervention and control groups respectively (P = 0.08). There were no significant differences in demographic data between the groups (P > 0.05). Nasal obstruction, post nasal drip (PND), reduced sense of smell, quality of life, CT scan and rhinoscopy scores were not significantly different between the two groups after intervention (P > 0.05). Facial pain severity score was significantly more reduced in intervention group in comparison with control group (P < 0.01). Conclusions: We concluded that application of Amphotericin B as an adjunctive medication to other common treatments, does not seemto be an efficientmethod for improvement of CRS symptoms.


  1. 1.Krous JHCS, Gordon BR, Derebery MJ. Allergy and immunology. 17 ed. Philadelphia: Lippincott Williams and Wilkings; 2002. pp. 221–3.

    1. Hsu J, Peters AT. Pathophysiology of chronic rhinosinusitis with nasal polyp. Am J Rhinol Allergy. 2011;25(5):285–90. doi: 10.2500/ajra.2011.25.3680. [PubMed: 22186239].
    2. Choi SSGK, Kennedy DW, Bolger WE, Zinreich SJ. Complications in sinus disease. 14 ed. London: B. C. Decker Inc; 2001.
    3. Kern RC, Conley DB, Walsh W, Chandra R, Kato A, Tripathi-Peters A, et al. Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis. Am J Rhinol. 2008;22(6):549–59. doi: 10.2500/ajr.2008.22.3228. [PubMed: 18786300].
    4. National Center for Health Statistics. . Summary health statistics for us adults, 1997, Data form the national health interview survey. ; 2002.
    5. Kohatsu W. Complementary and alternative medicine secrets. Philadelphia: Hanley and Belfus; 2002.
    6. Kennedy DW, Bolger WE, Zinreich SJ. Diseases of the sinuses, diagnosis and management. Canada: PMPH, USA; 2001.
    7. Nuutinen J, Holopainen E, Haahtela T, Ruoppi P, Silvasti M. Balanced physiological saline in the treatment of chronic rhinitis. Rhinology. 1986;24(4):265–9. [PubMed: 3823748].
    8. Rudert H, Maune S, Mahnke CG. [Complications of endonasal surgery of the paranasal sinuses. Incidence and strategies for prevention]. Laryngorhinootologie. 1997;76(4):200–15. doi: 10.1055/s-2007-997414. [PubMed: 9264594].
    9. May M, Levine HL, Mester SJ, Schaitkin B. Complications of endoscopic sinus surgery: analysis of 2108 patients–incidence and prevention. Laryngoscope. 1994;104(9):1080–3. doi: 10.1288/00005537-199409000- 00006. [PubMed: 8072353].
    10. Levine HL. Functional endoscopic sinus surgery: evaluation, surgery, and follow-up of 250 patients. Laryngoscope. 1990;100(1):79–84. doi: 10.1288/00005537-199001000-00016. [PubMed: 2293704].
    11. Wackym PA, Rice DH, Schaefer SD. Minimally invasive surgery of the head, neck, and cranial base. Philadelphia: Lippincott Williams and Wilkins; 2002.
    12. Rice DH, Schaefer SD, Calver LE. Endoscopic paranasal sinus surgery. Philadelphia: Lippincott Williams and Wilkins; 2004.
    13. Hosemann W. Minimally invasive endonasal sinus surgery thieme. 1 ed. New York: Stuttgart; 2000.
    14. Hamilos DL, Lund VJ. Etiology of chronic rhinosinusitis: the role of fungus. Ann Otol Rhinol Laryngol Suppl. 2004;193:27–31. [PubMed: 15174758].
    15. Ponikau JU, Sherris DA. The role of airborne mold in chronic rhinosinusitis. J Allergy Clin Immunol. 2006;118(3):762–3. doi: 10.1016/j.jaci.2006.06.035. [PubMed: 16950303].
    16. Shin SH, Ponikau JU, Sherris DA, Congdon D, Frigas E, Homburger HA, et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol. 2004;114(6):1369–75. doi: 10.1016/j.jaci.2004.08.012. [PubMed: 15577837].
    17. Ponikau JU, Sherris DA, Kephart GM, Adolphson C, Kita H. The role of ubiquitous airborne fungi in chronic rhinosinusitis. Clin Rev Allergy Immunol. 2006;30(3):187–94. doi: 10.1385/criai:30:3:187.
    18. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses. 1998;41(7-8):309–19. [PubMed: 9861837].
    19. Ponikau JU, Sherris DA, Weaver A, Kita H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol. 2005;115(1):125–31. doi: 10.1016/j.jaci.2004.09.037. [PubMed: 15637558].
    20. Ebbens FA, Scadding GK, Badia L, Hellings PW, Jorissen M, Mullol J, et al. Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2006;118(5):1149–56. doi: 10.1016/j.jaci.2006.07.058. [PubMed: 17088142].
    21. Ricchetti A, Landis BN, Maffioli A, Giger R, Zeng C, Lacroix JS. Effect of anti fungal nasal lavage with amphotericin B on nasal polyposis. J Laryngol Otol. 2002;116(4):261–3. [PubMed: 11945184]. 23. Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993;31(4):183–4. [PubMed: 8140385]. 24. Ponikau JU, Sherris DA, Kita H, Kern EB. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2002;110(6):862–6. [PubMed: 12464951].
    22. Liang KL, Su MC, Shiao JY, Tseng HC, Hsin CH, Lin JF, et al. Amphotericin B irrigation for the treatment of chronic rhinosinusitis without nasal polyps: a randomized, placebo-controlled, doubleblind study. Am J Rhinol. 2008;22(1):52–8. doi: 10.2500/ajr.2008.22.3115. [PubMed: 18284860].
    23. Shin SH, Ye MK. Effects of topical amphotericin B on expression of cytokines in nasal polyps. Acta Otolaryngol. 2004;124(10):1174–7. [PubMed: 15768813].
    24. Ebbens FA, Georgalas C, Luiten S, van Drunen CM, Badia L, Scadding GK, et al. The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: a multicenter randomized controlled study. Laryngoscope. 2009;119(2):401–8. doi: 10.1002/lary.20064. [PubMed: 19160404].
    25. Weschta M, Rimek D, Formanek M, Polzehl D, Podbielski A, Riechelmann H. Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol. 2004;113(6):1122–8. doi: 10.1016/j.jaci.2004.03.038. [PubMed: 15208594]. 29. Helbling A, Baumann A, Hanni C, Caversaccio M. Amphotericin B nasal spray has no effect on nasal polyps. J Laryngol Otol. 2006;120(12):1023–5. doi: 10.1017/S0022215106002167. [PubMed: 16965642].
    26. Gerlinger I, Fittler A, Fonai F, Patzko A, Mayer A, Botz L. Postoperative application of amphotericin B nasal spray in chronic rhinosinusitis with nasal polyposis, with a review of the antifungal therapy. Eur Arch Otorhinolaryngol. 2009;266(6):847–55. doi: 10.1007/s00405-008-0836- 0. [PubMed: 18953552].